News

John West, Solexa Ltd’s chief executive, has assumed the chief executive position of the combined company, which will be headquartered in California. The board of Solexa Inc will

Evotec Neurosciences (ENS) discovers and develops therapeutics for the treatment of Alzheimer’s disease and other central nervous system (CNS) disorders with high unmet medical needs. The acquisition will

External Independent Data Monitoring Committee (IDMC) analyses of both phase III trials exceeded the pre-specified value for stopping the trials, as the IDMC found a statistically significant improvement

The financing will take place in two closings. In the first closing, investors will purchase $2,000,000 of Series D preferred stock and warrants. The second closing, for which

Previous studies have shown that aspirin resistance is associated with triple the risk of heart attack, stroke and death. Once patients are tested and identified as aspirin resistant,

The new funding allocations include stem cell research and DNA-based medicines and will provide a huge boost to British science, which is already world class. The allocations come

The results of a safety analysis, which was performed as a secondary endpoint, suggest that Seroquel (quetiapine fumarate) did not increase the risk of cerebrovascular adverse events (CVAEs)

The Respiratory Disease Network (RDN) is a group of three compounding pharmacies established by SourceCF in September 2004. The litigation concerned the marketing of a compounded formulation of

Griseofulvin oral suspension, USP 125mg/5mL, acts systemically to inhibit the growth of trichophyton, mMicrosporum, and epidermophyton genera of fungi. Major indications for the product are tinea capitis (ringworm